NSE · NEPHROCARE · Healthcare
Nephro Care India Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹27 Cr with net profit ₹1 Cr — a 3.74% net margin, versus 1.85% the period before.
Shareholding
As of 2026-06-30
- Promoter61.71%
- Public36.03%
- FII0.96%
- DII1.29%
1,900 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.66× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Healthcare · ranked #36 of 79 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,28,472 Cr | 242.67 | 13.55 | 20.48% | 7.7% |
| Max Healthcare Institute Ltd. | ₹1,08,166 Cr | 315.74 | 10.06 | 13.42% | 17.23% |
| Fortis Healthcare Ltd. | ₹71,876 Cr | 270.47 | 7.26 | 10.53% | 11.41% |
| Narayana Hrudayalaya Ltd. | ₹42,315 Cr | 187.89 | 9.33 | 17.76% | 10.2% |
| Aster DM Healthcare Ltd. | ₹42,227 Cr | 299.63 | 9.23 | 8.48% | 8.36% |
| Global Health Limited | ₹38,526 Cr | 267.33 | 9.72 | 14.05% | 12.62% |
| Krishna Institute of Medical Sciences Ltd. | ₹31,931 Cr | 752.83 | 14.2 | 10.74% | 6.18% |
| Dr. Lal Path Labs Ltd. | ₹31,558 Cr | 239.5 | 12.58 | 20.13% | 18.27% |
| Poly Medicure Ltd. | ₹17,015 Cr | 256.67 | 5.48 | 10.37% | 17.18% |
| Dr. Agarwal's Health Care Limited | ₹15,494 Cr | 391.04 | 7.65 | 6.58% | 6.4% |
| Nephro Care India Limited(this company) | ₹104 Cr | 103.2 | 1.83 | 5.93% | 3.71% |
AI analysis
AI-generated · google/gemini-2.5-flashNephro Care India Limited operates in the Healthcare sector with a market capitalization of Rs 106 Cr. The company has a PE ratio of 105.33 and an EPS of 2.04. The debt-to-equity ratio is 0.
Positives
- +The company has a debt-to-equity ratio of 0, indicating no debt.
- +Promoter holding of 61.71% as of March 2026 is substantial.
- +Annual revenue has consistently increased from Rs 17.09 Cr in March 2023 to Rs 47.56 Cr in March 2025.
Negatives
- −The profit margin is 0%, indicating no reported profit margin from the provided data.
- −Net Profit decreased from Rs 4.41 Cr in March 2024 to Rs 3.64 Cr in March 2025.
- −The EPS decreased from Rs 3.80 in March 2024 to Rs 2.38 in March 2025.
- −The company is under ESM 1 surveillance.
- −Promoter holding decreased from 61.44% in March 2025 to 61.71% in March 2026.
Financial performance
Revenue increased from Rs 17.09 Cr in March 2023 to Rs 27.60 Cr in March 2024, and further to Rs 47.56 Cr in March 2025. Net profit also increased from Rs 2.37 Cr in March 2023 to Rs 4.41 Cr in March 2024, before decreasing to Rs 3.64 Cr in March 2025.
Profitability & returns
The company reported a Return on Equity (ROE) of 5.93% and a Return on Capital Employed (ROCE) of 8.44%. The profit margin is 0%. EPS was 2.37 in March 2023, increasing to 3.80 in March 2024, and then decreasing to 2.38 in March 2025.
Balance sheet
The company has a book value of Rs 34.49. The debt-to-equity ratio stands at 0, indicating no debt. No dividend yield is reported.
Ownership & pledges
As of March 2026, promoters held 61.71% of the shares. Public shareholding was 36.27%, while DIIs held 1.30% and FIIs held 0.73%. There are no reported promoter pledges.
Regulatory & surveillance
The company is currently under ESM (Enhanced Surveillance Measure) Stage 1, indicating increased scrutiny.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.